| pubmed-article:8438874 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8438874 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:8438874 | lifeskim:mentions | umls-concept:C0007589 | lld:lifeskim |
| pubmed-article:8438874 | lifeskim:mentions | umls-concept:C0237881 | lld:lifeskim |
| pubmed-article:8438874 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:8438874 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:8438874 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:8438874 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:8438874 | lifeskim:mentions | umls-concept:C1511938 | lld:lifeskim |
| pubmed-article:8438874 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8438874 | pubmed:dateCreated | 1993-3-22 | lld:pubmed |
| pubmed-article:8438874 | pubmed:abstractText | Bromodeoxyuridine (BrdU) was administered to 86 newly diagnosed patients with standard risk acute myeloid leukemia (AML) prior to starting induction therapy and the labeling index (LI), durations of S-phase (Ts), and the cell cycle (Tc) of myeloblasts were determined. Induction therapy with cytosine arabinoside and daunomycin was subsequently started. Bone marrow biopsies were obtained on days 6 and 17 and weekly thereafter, and were treated with a monoclonal anti-BrdU antibody to determine the fate of cells labeled on day 0 by BrdU. BrdU labeled granulocytes indicating the presence of in vivo differentiation (Diff+) were identified in 48 patients ranging from 1+ (1-10 labeled cells) to 4+ (greater than 31 labeled granulocytes). When compared to 38 differentiation negative (Diff-) patients, Diff+ group had longer Ts (14.5 hr vs. 10.95 hr, P = 0.015) and Tc (59.7 hr vs. 41.7 hr, P = 0.017). Remission duration was significantly longer (no median) for 3-4+ Diff+ as compared to Diff- (median = 220 days) patients (Wilcoxon P = 0.04). We conclude that the detection of in vivo differentiation in AML patients indicates a favorable long-term prognosis either due to the presence of a substantial amount of normal residual hematopoiesis prior to starting induction therapy or due to the ability of leukemic cells to undergo differentiation. | lld:pubmed |
| pubmed-article:8438874 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8438874 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8438874 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8438874 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8438874 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8438874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8438874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8438874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8438874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8438874 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8438874 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8438874 | pubmed:issn | 0361-8609 | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:BarcosMM | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:GartsidePP | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:WhiteMM | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:PreislerHH | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:LampkinBB | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:RazaAA | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:YousufNN | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:SheikhYY | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:LykinsJJ | lld:pubmed |
| pubmed-article:8438874 | pubmed:author | pubmed-author:KuklaCC | lld:pubmed |
| pubmed-article:8438874 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8438874 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:8438874 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8438874 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8438874 | pubmed:pagination | 147-57 | lld:pubmed |
| pubmed-article:8438874 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:meshHeading | pubmed-meshheading:8438874-... | lld:pubmed |
| pubmed-article:8438874 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8438874 | pubmed:articleTitle | Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. | lld:pubmed |
| pubmed-article:8438874 | pubmed:affiliation | Roswell Park Memorial Institute, Buffalo, New York. | lld:pubmed |
| pubmed-article:8438874 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8438874 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8438874 | lld:pubmed |
